BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19906113)

  • 1. The role of entecavir in preventing hepatitis B recurrence after liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Wang X; Shen CH; Luo Y; Xin TY; Wang SY; Qiu DK
    J Dig Dis; 2009 Nov; 10(4):321-7. PubMed ID: 19906113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
    Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
    Fung J; Chan SC; Cheung C; Yuen MF; Chok KS; Sharr W; Chan AC; Cheung TT; Seto WK; Fan ST; Lai CL; Lo CM
    Am J Gastroenterol; 2013 Jun; 108(6):942-8. PubMed ID: 23629601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation.
    Wang ZX; Ding GS; Fu H; Zhang JJ; Chen XS; Guo WY; Shi XM; Fu ZR
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):345-8. PubMed ID: 15313666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.